ReviewInternational journal of clinical oncology2008
Chemotherapy for metastatic gastric cancer in Japan.
Review in International journal of clinical oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.PloS one · 2013Pooled it
- Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2016Article
- Taxanes in the Treatment of Advanced Gastric Cancer.Molecules (Basel, Switzerland) · 2016Review
- The α7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to taxanes.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Surgery for recurrent biliary carcinoma: results for 27 recurrent cases.World journal of surgical oncology · 2015Article
- Metastatic gastric cancer treatment: a little slow but worthy progress.Medical oncology (Northwood, London, England) · 2013Review
- REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer.British journal of cancer · 2013Article
- Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.The Journal of biological chemistry · 2012Article
- Critical appraisal of trastuzumab in treatment of advanced stomach cancer.Cancer management and research · 2011Article
- Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard?Current treatment options in oncology · 2011Review
- Lymph node dissection in the resection of gastric cancer: review of existing evidence.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2010Review
- Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.International journal of clinical oncology · 2010Article
- Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers.International journal of clinical oncology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until the 1990s, there were no chemotherapy regimens with old-generation anticancer agents showing a survival benefit over 5-fluorouracil (FU) alone, and standard chemotherapy for metastatic gastric cancer had not been established. In the late 1990s, several new active agents were developed and some phase III trials with these agents were conducted; the new agent S-1 showed noninferiority to 5-FU in these trials. S-1 plus cisplatin is the first doublet chemotherapy to have shown a survival benefit over monotherapy with S-1. It has been demonstrated that capecitabine and oxaliplatin (OHP) can replace 5-FU and cisplatin (CDDP), offering more convenient treatment options. Thus, combination chemotherapy with an oral fluoropyrimidine (S-1 or capecitabine) and platinum (CDDP or OHP) has been recognized as standard chemotherapy for metastatic gastric cancer all over the world. However, it can be said that none of these new combination chemotherapies have shown remarkable progress from 5-FU plus cisplatin regimens. It is expected that triplet chemotherapy with a taxane; the use of molecular targeting agents; and the establishment of treatment strategies including second line chemotherapy, will lead to remarkable progress in personalized medicine in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.